Matches in Wikidata for { <http://www.wikidata.org/entity/Q65474886> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q65474886 description "clinical trial" @default.
- Q65474886 description "ensayu clínicu" @default.
- Q65474886 description "klinisch onderzoek" @default.
- Q65474886 description "клінічне випробування" @default.
- Q65474886 name "A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease" @default.
- Q65474886 name "A 12-Week Safety and Pharmacodynamic Study of AT1001" @default.
- Q65474886 type Item @default.
- Q65474886 label "A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease" @default.
- Q65474886 label "A 12-Week Safety and Pharmacodynamic Study of AT1001" @default.
- Q65474886 prefLabel "A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease" @default.
- Q65474886 prefLabel "A 12-Week Safety and Pharmacodynamic Study of AT1001" @default.
- Q65474886 P1050 Q65474886-A169F700-732E-49C5-BFBB-066B8A8BFD93 @default.
- Q65474886 P1132 Q65474886-EB7ECEC6-AACA-4C19-9FC2-82EEE1B70C80 @default.
- Q65474886 P1476 Q65474886-566B2DE7-7680-47DE-B6A9-088AC31981D6 @default.
- Q65474886 P17 Q65474886-0B0F5774-F1F5-48BF-80C6-313B961783D2 @default.
- Q65474886 P17 Q65474886-3B19A43C-5531-46C9-A190-B9A457BF83C8 @default.
- Q65474886 P17 Q65474886-70BF473A-8DCB-4576-B228-91C59D712834 @default.
- Q65474886 P17 Q65474886-DC9159D9-3F8C-4CB6-A3BA-BF15C493726B @default.
- Q65474886 P17 Q65474886-DF9FFF9F-0464-4AF8-8C92-83AC497BFCB7 @default.
- Q65474886 P17 Q65474886-F41F9EBB-71DF-4164-B520-C6AB9DD11F3E @default.
- Q65474886 P2899 Q65474886-CEAB920A-78D5-40D3-A882-861E62B894CA @default.
- Q65474886 P3098 Q65474886-D3D0C1F3-1909-4793-BC29-9A08257CB1AC @default.
- Q65474886 P31 Q65474886-4D147EBF-6CB6-4380-9968-C59D7A711FA0 @default.
- Q65474886 P4135 Q65474886-6030CF80-2CA2-417D-9416-6E99F75090B3 @default.
- Q65474886 P580 Q65474886-B96AF4ED-F18C-4894-90A9-DE24230C99F7 @default.
- Q65474886 P582 Q65474886-8AB85C16-06C0-4388-9D81-0B89E2A91E72 @default.
- Q65474886 P6099 Q65474886-5B4E03F6-E42D-47F2-9A5E-B146AF4294D9 @default.
- Q65474886 P8363 Q65474886-09099B20-7801-4415-98D3-17B787FF91B8 @default.
- Q65474886 P1050 Q615645 @default.
- Q65474886 P1132 "+9" @default.
- Q65474886 P1476 "A Phase 2, Open-Label, Multiple Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Female Patients With Fabry Disease" @default.
- Q65474886 P17 Q142 @default.
- Q65474886 P17 Q145 @default.
- Q65474886 P17 Q155 @default.
- Q65474886 P17 Q16 @default.
- Q65474886 P17 Q30 @default.
- Q65474886 P17 Q408 @default.
- Q65474886 P2899 "+18" @default.
- Q65474886 P3098 "NCT00304512" @default.
- Q65474886 P31 Q30612 @default.
- Q65474886 P4135 "+65" @default.
- Q65474886 P580 "2006-09-07T00:00:00Z" @default.
- Q65474886 P582 "2008-05-09T00:00:00Z" @default.
- Q65474886 P6099 Q42824440 @default.
- Q65474886 P8363 Q78089383 @default.